MY177001A - Phenothiazine compounds for treating mild cognitive impairment - Google Patents

Phenothiazine compounds for treating mild cognitive impairment

Info

Publication number
MY177001A
MY177001A MYPI20095255A MYPI20095255A MY177001A MY 177001 A MY177001 A MY 177001A MY PI20095255 A MYPI20095255 A MY PI20095255A MY PI20095255 A MYPI20095255 A MY PI20095255A MY 177001 A MY177001 A MY 177001A
Authority
MY
Malaysia
Prior art keywords
cognitive impairment
mild cognitive
treating mild
phenothiazine compounds
phenothiazine
Prior art date
Application number
MYPI20095255A
Other languages
English (en)
Inventor
Claude Michel Wischik
Gernot Riedel
Dominic Venay Harbaran
Serena Deiana
Damon Jude Wischik
Roger Todd Staff
Elizabeth Anne Goatman
Alison Dorothy Murray
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MY177001A publication Critical patent/MY177001A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20095255A 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment MY177001A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
MY177001A true MY177001A (en) 2020-09-01

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20095255A MY177001A (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Country Status (16)

Country Link
US (1) US9211294B2 (cg-RX-API-DMAC7.html)
EP (1) EP2167095B1 (cg-RX-API-DMAC7.html)
JP (1) JP5725605B2 (cg-RX-API-DMAC7.html)
CN (1) CN101820884B (cg-RX-API-DMAC7.html)
AU (1) AU2008265045B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813670A2 (cg-RX-API-DMAC7.html)
CA (1) CA2690746C (cg-RX-API-DMAC7.html)
DK (1) DK2167095T3 (cg-RX-API-DMAC7.html)
ES (1) ES2739546T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191513T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045460T2 (cg-RX-API-DMAC7.html)
MY (1) MY177001A (cg-RX-API-DMAC7.html)
PL (1) PL2167095T3 (cg-RX-API-DMAC7.html)
PT (1) PT2167095T (cg-RX-API-DMAC7.html)
SI (1) SI2167095T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008155533A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384741B (zh) 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
PL2205245T3 (pl) * 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
AU2011358840B2 (en) * 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
PL3470390T3 (pl) * 2013-01-30 2023-11-06 Ecolab Usa Inc. Zmiatacze siarkowodoru
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
WO2016133995A1 (en) * 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
EP4223297A3 (en) * 2016-07-25 2023-11-15 WisTa Laboratories Ltd. Administration and dosage of diaminophenothiazines
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI3826639T3 (fi) * 2018-07-26 2024-10-30 Wista Lab Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
PT1799662E (pt) * 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
EP2001556B1 (en) * 2006-03-29 2014-10-01 Wista Laboratories Ltd. Thioninium compounds and their use
CN101460157B (zh) * 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
CN109384741B (zh) * 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2457904T3 (en) 2006-07-11 2015-01-12 Wista Lab Ltd Methods for the synthesis and / or purification of the compounds diaminophenothiazinium

Also Published As

Publication number Publication date
CN101820884A (zh) 2010-09-01
SI2167095T1 (sl) 2019-09-30
WO2008155533A3 (en) 2009-02-19
JP5725605B2 (ja) 2015-05-27
PT2167095T (pt) 2019-08-06
EP2167095B1 (en) 2019-05-29
AU2008265045B2 (en) 2014-02-27
HUE045460T2 (hu) 2019-12-30
DK2167095T3 (da) 2019-07-29
BRPI0813670A2 (pt) 2014-12-30
PL2167095T3 (pl) 2019-11-29
US20100184752A1 (en) 2010-07-22
CN101820884B (zh) 2013-08-28
WO2008155533A2 (en) 2008-12-24
EP2167095A2 (en) 2010-03-31
CA2690746A1 (en) 2008-12-24
AU2008265045A1 (en) 2008-12-24
JP2010530403A (ja) 2010-09-09
CA2690746C (en) 2018-01-02
ES2739546T3 (es) 2020-01-31
HRP20191513T1 (hr) 2019-11-29
US9211294B2 (en) 2015-12-15

Similar Documents

Publication Publication Date Title
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
NL301145I1 (cg-RX-API-DMAC7.html)
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
NZ593474A (en) Compositions and methods for treatment of celiac disease
MX394667B (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4- ciano-3-trifluorometll-fen|l)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ilideno]-tiourea.
TW200716624A (en) Compounds for modulating TRPV3 function
TNSN08400A1 (en) Organic compounds and their uses
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EP1924293A4 (en) COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
ZA201002764B (en) Benzodiazepinone compounds useful in the treatment of skin conditions
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY155340A (en) Use of cathepsin c
TW200716088A (en) Formulations and methods for treating amyloidosis
TW200716015A (en) Methods and apparatuses for sealing ophthalmic lens packages